A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer

• Published in: Clinical cancer research Vol. 26; no. 5; pp. 990 - 999
• Main Authors: Corn, Paul G, Zhang, Miao, Nogueras-Gonzalez, Graciela M, Xiao, Lianchun, Zurita, Amado J, Subudhi, Sumit K, Tu, Shi-Ming, Aparicio, Ana M, Coarfa, Cristian, Rajapakshe, Kimal, Huang, Shixia, Navone, Nora M, Lin, Sue-Hwa, Wang, Guocan, Ramachandran, Sumankalai, Titus, Mark A, Panaretakis, Theocharis, Gallick, Gary E, Efstathiou, Eleni, Troncoso, Patricia, Logothetis, Christopher
• Format: Journal Article
• Language: English
• Published: United States 01.03.2020
• Subjects: Aged; Aged, 80 and over; Androgen Antagonists - therapeutic use; Anilides - therapeutic use; Biomarkers, Tumor - metabolism; Bone Neoplasms - drug therapy; Bone Neoplasms - secondary; Drug Therapy, Combination; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - pathology; Pyridines - therapeutic use; Survival Rate

Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa)....